COVID-19’s impact on care leads 2020 glaucoma news
Click Here to Manage Email Alerts
The impact of COVID-19 on health care dominated the news in 2020, including glaucoma care. Also popular were advances in both medical and surgical treatments for glaucoma.
Read Healio/OSN’s top-performing glaucoma articles from 2020:
VIDEO: How coronavirus affects glaucoma patient care in a private practice
Jason Bacharach, MD, medical director and founding partner at North Bay Eye Associates in the San Francisco Bay area, discusses how he has adjusted the way he treats his patients with glaucoma during the COVID-19 pandemic. Watch more.
iDose lowers IOP, shows no significant adverse events in phase 2 trial
The iDose, a titanium implant from Glaukos for continuous drug delivery, has shown positive phase 2 results and is currently in a phase 3 program, according to a speaker. Read more.
New World Medical registers KDB Glide with FDA
The FDA has registered New World Medical’s KDB Glide as a Class 1 device, which will soon be available in the U.S., according to a company press release. Read more.
Biodegradable Durysta approved to lower IOP
Durysta, the first intracameral biodegradable sustained-release implant designed to lower IOP in patients with open-angle glaucoma or ocular hypertension, has been approved by the FDA, Allergan announced in a press release. Read more.
LiGHT trial shows more visual field progression with medication vs. laser
Secondary analysis of the LiGHT trial showed that patients treated first with medications were more likely to undergo rapid visual field progression than those treated first with selective laser trabeculoplasty. Read more.
Collapse
Healio Coverage
Read more about
Click Here to Manage Email Alerts